Document Detail


Epoetin beta: new indication. Preparation for IV-SC injection: erythrocyte growth factor.
MedLine Citation:
PMID:  10183393     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
According to an unreliable meta-analysis, epoetin beta reduces the number of premature neonates needing transfusions for anaemia by 18% on average. When such children do require transfusions, two comparative trials have shown a reduction in the frequency of transfusions and total volume of blood transfused, but the clinical consequences were not studied. Thus clinical experience to date is too limited to rule out a risk of possibly severe adverse events. Furthermore, prescription of epoetin beta must be accompanied by iron supplementation, whose optimal dose and route of administration have not been established. The cost-benefit ratio of epoetin beta in the prevention of anaemia in premature infants must be thoroughly assessed in the context of national health systems.
Authors:
-
Related Documents :
7375243 - Failure of strychnine treatment during the neonatal period in three finnish children wi...
21298093 - Cause of death affects racial classification on death certificates.
24370213 - An epidemiological survey on low birth weight infants in china and analysis of outcomes...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Prescrire international     Volume:  7     ISSN:  1167-7422     ISO Abbreviation:  Prescrire Int     Publication Date:  1998 Feb 
Date Detail:
Created Date:  1998-09-24     Completed Date:  1998-09-24     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9439295     Medline TA:  Prescrire Int     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  13-5     Citation Subset:  T    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Neonatal / prevention & control*
Blood Transfusion
Clinical Trials as Topic
Cost-Benefit Analysis
Erythropoietin* / administration & dosage,  adverse effects,  therapeutic use
France
Humans
Infant, Newborn
Infant, Premature
Infection / chemically induced
Iron / deficiency
Iron, Dietary
Meta-Analysis as Topic
Treatment Outcome
Chemical
Reg. No./Substance:
0/Iron, Dietary; 11096-26-7/Erythropoietin; 7439-89-6/Iron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tramadol: new preparation. Capsules: central analgesic; step 2 on the WHO scale.
Next Document:  Pneumococcal vaccine: a second look. Solution for SC or IM injection: pneumococcal vaccine.